|
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. We have leveraged the knowledge and skills of our seasoned team to create a portfolio of therapies with the potential to revolutionize medical practice. Our current product pipeline consists of small-molecule drugs in development to treat three large, unmet medical needs—Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer.
|
